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Abstract Mammalian mitochondrial deoxyguanosine kinase 
(dGK) is responsible for phosphorylation of purine deoxyribo- 
nucleosides in the mitochondrial matrix. Using a RT-PCR- 
generated probe, based on amino acid sequence information from 
proteolytic fragments of purified bovine dGK, we have cloned a 
cDNA from a human brain cDNA library that encodes a 30 kDa 
protein. The deduced amino acid sequence of this protein included 
the sequence of all six peptides isolated and sequenced from 
purified dGK. Expression and purification of recombinant 
protein from induced Escherichia coli extracts revealed that it 
catalyses efficient phosphorylation of dGuo, arabinosyl guanine, 
dAdo, 2-chloro-2'-deoxyadenosine and dlno similar to purified 
dGK. Northern blot analysis demonstrated one dominant positive 
mRNA of 1.35 kb and it was found in several tissues at similar 
levels. The coding sequence of dGK showed 46% identity to the 
coding sequence of cytosolic deoxycytidine kinase, and conserved 
sequence motifs among the known deoxynucleoside kinase were 
identified. 
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I. Introduction 
Mammalian deoxyguanosine kinase (dGK, NTP:deoxygua- 
nosine 5'-phosphotransferase, EC 2.7,1. 113) is a nuclear 
coded enzyme localised to the mitochondria (mt), catalysing 
the phosphorylation of purine deoxynucleosides and their 
analogs, using a nucleoside triphosphate as phosphate donor. 
dGK activity is found in most tissues and the enzyme has 
been purified from skin, thymus, placenta, liver, brain and 
leukemic cells [1-8]. The active form of dGK is a dimer of 
28-29 kDa subunits and dGuo, dAdo, dlno and several cyto- 
static analogs, e.g. arabinosyl guanine (AraG) and 2-chloro- 
2'-deoxyadenosine (CdA) can serve as substrates [1,8]. The 
cytosolic enzyme deoxycytidine kinase (dCK) has an overlap- 
ping substrate specificity with that of dGK but can in addition 
phosphorylate several pyrimidine nucleosides. There have 
been considerable difficulties in distinguishing the dGK and 
dCK activities in extracts from different issues [1,9]. In pro- 
liferating cells and lymphoid tissues dCK is found at much 
higher levels than dGK, but in many resting cells such as 
nerve cells and muscle cells dGK is the only purine deoxynu- 
cleoside phosphorylating enzyme present [1]. It is still unclear 
if the activity of dGK contributes to the pharmacological 
effects of cytostatic and antiviral purine analogs. 
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One form of severe combined immunodeficiency in man is 
associated with purine nucleoside phosphorylase (PNP) defi- 
ciency [10]. Increased salvage of purine deoxynucleosides, 
leading to accumulation of toxic levels of dGTP in lympho- 
cytes, is the assumed mechanism of the disease [10]. Snyder et 
al. [11] have developed a mutant mouse strain lacking PNP 
activity and they observed that in all tissues from the mutant 
mice there was also a reduction of the dGK activity. This 
latter deficiency most likely protected the PNP mutants 
from the toxicity of dGuo, demonstrating a central role for 
dGK in the pathogenesis of PNP deficiency. 
It is important o evaluate nucleoside analogs used in che- 
motherapy for their effects on mtDNA synthesis, since it is 
known that several nucleoside analogs are selective inhibitors 
of mtDNA polymerase. Treatment with the anti-HIV drugs, 
3'-azido-2'-deoxythymidine, 2'-3'-dideoxycytidine and 2'-3'- 
dideoxyinosine, leads to decreased mtDNA synthesis which 
ultimately gives myophaties and neurophaties as serious side 
effects [12]. The accumulation of defect mtDNA has been 
observed in many tissues in degenerative disorders, as well 
as in normal aging, and discussed as an important contribut- 
ing factor in these processes [13]. A decreased supply of 
mtDNA precursors may be one of the causes of mtDNA 
deletions. 
A complete purification protocol for dGK has been devel- 
oped starting from bovine brain [8] and we have used infor- 
mation from peptide sequences determined from this material 
to clone the cDNA for human dGK. The resulting cDNA 
encodes a 30 kDa protein with extensive homology to the 
coding sequence of human dCK [9]. The cloning of dGK 
may enable the evaluation of its role in mitochondrial DNA 
precursor synthesis, in inherited immunodeficiency disease and 
in chemotherapy with purine nucleoside analogs. 
2. Materials and methods 
2.1. Materials 
Radiolabelled nucleotides, [ct-3~S]dATP (1000 Ci/mmol), [7-32p]ATP 
(3000 Ci/mmol) and [a-32p]dCTP (3000 Ci/mmol) were obtained from 
Amersham Corp. 9-~-o-[8-SH]arabinofuranosylguanine (9 Ci/mmol) 
was from Moravek Biochemicals Inc. CA. IPTG (isopropyl-13-thioga- 
lactopyranoside) and restriction enzymes were from Promega. All 
other materials and reagents were of the highest quality available. 
2.2. Purification of bovine dGK 
About 1 kg of calf brain was homogenised and proteins extracted as 
described [8]. The crude extract was treated with streptomycin sul- 
phate and then subjected to DEAE chromatography, whereby the 
dGK-containing fractions (assayed with [ZH]AraG as substrate) 
were identified. These fractions were diluted and applied to a hydro- 
xylapatite column, proteins were eluted with a KC1 gradient as de- 
scribed [8]. 
In the last purification step we exchanged the 3'-dGMP-Sepharose 
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by an ATP-agarose chromatography as follows: 150 ml of the dGK 
pool from hydroxyl apatite chromatography was applied to a 5 ml 
ATP-agarose column (C-8 coupled with a 9 carbon linker from Sig- 
ma) which was equilibrated with buffer B (10 mM potassium phos- 
phate, pH 7.6, containing 5 mM MgC12, 1 mM EDTA, 1 mM dithio- 
threitol and 15% glycerol). After washing the column with 100 ml of 
buffer B, dGK was eluted with 5 mM ATP in buffer B. Fractions were 
collected and assayed for dGK activity and fractions that showed 
dGK activity were precipitated and analysed by SDS-PAGE as de- 
scribed [8]. 
2.3. Sequence determination ofproteolytic fragments 
The 28 kDa protein band was excised and subjected to proteolytic 
cleavage, essentially as described [14]. In brief, the gel piece was 
washed with a mixture of digestion buffer and acetonitrile and then 
completely dried under a stream of nitrogen. During rehydration with 
buffer, modified trypsin (Promega) or endoproteinase LysC (WAKO) 
was added. Rehydration was continued until the gel piece had swollen 
to original shape. After overnight incubation at 30°C, the supernatant 
was saved and combined with extracts from the gel piece. Generated 
peptides were then isolated by reverse-phase liquid chromatography, 
using a SMART System (Pharmacia Biotech AB, Uppsala, Sweden). 
Selected peptides were sequence determined on an Applied Biosystems 
Model 470A instrument, following the manufacturer's instruction. 
2.4. PCR amplification of a dGK cDNA fragment 
All dGK peptide sequences were used to search the GenBank data 
base with the BLAST program. One of the peptide sequence 
(VQLEPFPEK) matched a sequence from the EST (expressed se- 
quence tag) data base with the accession o. R70551 (a 424 bp frag- 
ment). Based on this information two oligonucleotide primers were 
synthesized, (sense primer: 5'-CAGAATGGCACGTAGCTACA- 
GAACCT; antisense primer: 5'-TTTGCAAAGATATACCTGT- 
CACTGT), and used in a RT-PCR reaction to amplify a dGK-spe- 
cific DNA fragment of 278 bp, starting with human brain cDNA 
(prepared by using the Maraton TM cDNA amplification kit from 
Clontech Laboratories, Inc.). PCRs were performed in a total volume 
of 50 I.tl with 200 nM of each primer, 200 ~tM dNTPs, 2.5 mM MgCI2 
in 1 X polymerase buffer and 2.5 U of Expend TM High Fidelity en- 
zyme (Boehringer Mannheim). The reaction mixture was denatured at 
94°C for 1 min and followed by 30 cycles of denaturation at94°C for 
30 s, annealing at 60°C for 30 s and extension at 72°C for 3 min. The 
278 bp PCR product was purified from the agarose gel and subcloned 
into the PCR II vector (Invitrogen Corporation) and sequenced. 
2.5. Isolation of cDNA clones 
A human brain cDNA library (Stratagene, La Jolla, CA), con- 
structed in the Lambda ZAP ® vector, was screened with the 278 bp 
fragment as probe, labelled with 32p (Random Primed DNA Labeling 
Kit, Boehringer Mannheim). Hybridization was carried out at 42°C in 
6 X SSC, 5 × Denhardt's solution, 0.1% SDS and 50% formamide for 
20 h, filters were washed at 42°C in 2× SSC, 0.1% SDS and auto- 
radiographed. A total of 6 positive ~, phages were isolated. The cDNA 
inserts were in vivo excised using the ExassistTM/SOLR TM system 
(Stratagene) in Bluescript (sk--) phagemid vector, following the pro- 
tocol provided by the supplier. Both strands were sequenced by the 
Sanger dideoxynucleotide method (Sequenase kit, United States Bio- 
chemicals) using synthetic oligonucleotide primers. 
2.6. Northern blot analysis 
Human Multi-Tissue Blot (Clontech) were used to determine dGK 
mRNA levels in different issues. Blots were probed with full-length 
dGK cDNA (32p labelled as described above) in 5× SSPE, 10× 
Denhardt's olution, 200 ~tg/ml freshly denatured salmon sperm 
DNA, 2% SDS and 50% formamide at 42°C for 20 h, washed in 
0.2x SSC, 0.1% SDS twice at 42°C and autoradiographed. 
2. 7. Expression and characterization f recombinant dGK protein 
Two oligonucleotides, which contained the 5'-fianking restriction 
sites NcoI or BamHI, were used to PCR amplify the dGK coding 
sequence. The resulting fragment was digested with NcoI and BamHI 
and subcloned into the pET-9d expression vector (Novagen, Madi- 
son). This vector provides a His-tag and a thrombin cleavage site 
fused to the N-terminal of the expressed protein. The recombinant 
dGK construct was transformed into pLysS BL21(DE3) cells [15]. 
Induction was performed for 2 h in the presence of 1 mM IPTG at 
37°C. The bacteria were lyzed in 5 vol. of 50 mM Tris-HCl, pH 7.6, 
50 mM NaC1, 1 mM EDTA, 2 mM dithiothreitol, 0.5% Triton X-100, 
and 140 ~tM phenylmethylsulfonyl fluoride by freezing and thawing. 
The lysate was centrifuged at 35 000 ×g for 90 min. dGK was purified 
by metal affinity (TALON, Clontech) column chromatography essen- 
tially as described in the manual and dGK activity was eluted with 
0.25 M imidazole and 0.5 M NaC1. Part of these fractions were pre- 
cipitated and analyzed by SDS-PAGE and the activity with several 
deoxynucleosides determined. 
2.8. Enzyme assays 
dGK activity was determined by using [aH]araG as substrate as 
described previously [8]. The phosphoryl transfer assay was performed 
with 100 gM [7-a2p]ATP (10 mCi/ml), 50 mM Tris-HC1, pH 7.6, 10 
mM MgC12, 100 mM KC1, 10 mM dithiothreitol, 0.5 mg/ml bovine 
serum albumin, purified dGK, and 10 gM or 200 gM of nucleoside in 
a total volume of 50 lal. The phosphorylated products were separated 
by thin layer chromatography and quantitated as described [8]. 
3. Results 
Earlier studies have shown that brain is a good source for 
the purification of mitochondrial  deoxynucleoside kinases 
[1,8]. Because of the difficulty to obtain human brain material 
we used calf brain as starting material. After homogenisat ion 
and streptomycin sulphate precipitation, proteins were puri- 
fied by DEAE-chromatography,  followed by hydroxyl apatite 
chromatography and affinity chromatography [8]. 
In the present dGK purification the dGMP-Sepharose step 
was exchanged by an ATP-agarose step. However, several 
addit ional proteins bind to the ATP-agarose, but dGK is 
the only protein in the molecular weight range around 28 
kDa. The overall recovery of dGK protein is approximately 
20%, i.e. 500 ~tg from 1 kg of brain. 
Affinity purified dGK preparations were precipitated, re- 
duced, carboxymethylated and subjected to SDS gel electro- 
phoresis. The 28 kDa protein band was excised and treated 
with trypsin or endoproteinase LysC and the resulting pep- 
tides separated by narrow-bore reverse-phase liquid chroma- 
tography. 
Six peptide sequences were determined and when the EST 
sequence data base was searched with the BLAST program a 
positive match was obtained with one of the peptides 
(VQLEPFPEK).  The EST sequence was 424 bp long and, 
based on this information, two primers were synthesized 
Table 1 
Phosphorylation of nucleosides by recombinant human dGK and 
bovine brain dGK 
Substrate Concentration Bovine dGK Human dGK* 
( ] . tM)  (nmol/min/mg protein) 
dGuo 10 3.2 4.3 
200 3.9 4.5 
dAdo 10 0.5 0.5 
200 10.1 4.8 
dlno 10 9.9 8.3 
200 13.3 8.3 
dCyd 200 0.6 1.2 
CdA 10 3.7 9.5 
200 23.7 13.7 
araG 10 1.3 2.9 
200 4.0 6.9 
The phosphoryl transfer assay was performed as described in Section 
2 and the values are from one typical experiment. 
*Recombinant human dGK. 
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that were used to generate a dGK RT-PCR fragment of 278 
nucleotides. This was used as probe for screening of a human 
brain cDNA library. 
The full-length cDNA sequence of human mitochondrial 
deoxyguanosine kinase is shown in Fig. 1. All the peptide 
sequences from the bovine dGK protein could be identified. 
The cDNA clone includes 11 bp 5'-untranslated region, a 780 
bp open reading frame that encodes a protein of 260 amino 
acids with a calculated molecular weight of 30 kDa, and 234 
bp of 3'-untranslated sequence containing a polyadenylation 
signal at position 993 followed by a poly(A) tail. 
The full-length dGK cDNA was used to probe Northern 
blots containing mRNA from different human tissues. As 
shown in Fig. 2, a major band of 1.35 kb was observed in 
all lanes with similar intensity, except in those from colon, 
kidney and peripheral blood leukocyte where it appeared to 
be reduced. A shorter transcript (=  1 kb) was seen in the 
mRNA from most tissues. The shortest ranscript found in 
pancreas, lung and heart are the same, but appear to differ 
from the shortest transcript in the kidney and placenta. Testis 
showed the highest expression of the 1.35 kb mRNA and 
there was no indication of a 1 kb band. This pattern of ex- 
pression is clearly different from that of human dCK, which 
showed the highest level of a 2.8 kb mRNA in spleen and 
thymus [18]. 
Insertion of the human dGK coding sequence in the pET- 
9d vector gave a 40-fold increased GK activity in crude ex- 
tracts. Purification of recombinant dGK from BL21(DE3) 
cells by metal affinity chromatography demonstrated a major 
protein band of approximately 32 kDa in SDS-PAGE (Fig. 
3). The N-terminal His-tag and thrombin cleavage site se- 
quences account for about 2-3 kDa of the total molecular 
weight of the fusion protein. The purified recombinant dGK 
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Fig. 1. eDNA and deduced amino acid sequence of human dGK. 
The initiator ATG and termination signal TAA as well as a possible 
polyadenylation signal are in bold letters. The peptide sequences de- 
termined from proteolytic digests of bovine dGK are underlined. 
This sequence will appear in the EMBL, GenBank and DDBJ nu- 
cleotide sequence databases under the accession umber X97386. 
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Fig. 2. Northern blot analysis of dGK mRNA levels in human tis- 
sues, using the multiple-tissue Northern blots from Clontech with 
2 gg of mRNA in each lane. The estimated size of the major dGK 
mRNA was 1.35 kb. 
had a specific activity of 5 nmol/min per mg protein, using 
AraG as substrate, equivalent to the activity of purified bo- 
vine dGK [8]. Purified recombinant dGK as well as bovine 
dGK showed similar activity with dGuo, dAdo, dIno, AraG 
and CdA in the phosphoryl transfer assay (Table 1). Some 
activity was also observed with high concentration of dCyd 
with both enzyme preparations. 
4. Discussion 
The cloning of mammalian dGK eDNA was achieved by 
using a peptide sequence from the bovine enzyme to identify 
an EST eDNA sequence. A PCR-generated GK probe was 
used for the screening of a human brain eDNA library and a 
1 kb cDNA, coding for a protein of 260 amino acids, was 
isolated. All six peptide sequences obtained from bovine dGK 
(a total of 41 amino acids) were identified in the deduced (260 
amino acids) human protein and thus human and bovine 
dGK show a high degree of homology. 
Northern blot analysis with the dGK cDNA as probe 
showed positive hybridisation with a major and two minor 
mRNA transcripts that were found in similar abundancy in 
most tissues in the multiple Northern blots, dGK cDNA con- 
tains in addition to the 780 bp coding region a 234 bp 3'- 
untranslated region including a poly(A) tail. The 5'-untrans- 
lated sequence described here is only 11 nucleotides and we do 
not know if the missing 300 nucleotides in the eDNA com- 
pared to the major mRNA species is due to an extended 5'- 
sequence or to the existence of an additional Y-polyadenyla- 
tion signal. The overall pattern of dGK mRNA expression is
in accordance with the enzyme activity levels measured earlier 
[1,8]. 
The expression of human dGK eDNA, cloned into the pET 
vector system of Studier et al. [15] led to production of a 32 
kDa protein which showed high enzyme activity with purine 
deoxynucleosides similar to that of purified bovine dGK. In 
SDS-PAGE analysis of recombinant dGK and purified dGK, 
the latter showed a lower apparent molecular mass, most 
likely due in part to proteolysis during the mitochondrial im- 
port process [16,17]. 
When the dGK sequence was used in a BLAST search 
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against he GenBank nucleotide sequence data base the best 
matches were to human [9], mouse [18] and rat [19] deoxycy- 
tidine kinase sequences. The similarity in the deduced protein 
sequence were overall 46% and in some regions as high as 
70%. Two Bacillus subtilis proteins (25.4 and 24.1 kDa, re- 
spectively) [20], one Fowl pox virus 25.9 kDa polypeptide [21] 
as well as a ictalurid herpes virus 1 [22] and a saimiriine 
herpes virus 1 thymidine kinase [23] are all part of a group 
of sequences that show considerably ower but still significant 
similarities to human dGK. The only other dGK protein se- 
quence present in the GenBank is that of Lactobacillus acid- 
ophilus [24]. In this case the dGK gene is arranged in tandem 
with the deoxyadenosine kinase gene to which it shows 65% 
identity. The Lactobacillus gene encodes for a 26 and a 25 
kDa polypetide, respectively, which form an active heterodi- 
mer with dAK and dGK activity [24]. The identity between 
the Lactobacillus and the mammalian dGK is only 13%, but 
some interesting regions of conserved amino acids sequence 
can be observed (Fig. 4). 
In the very N-terminal part of the protein there is little 
homology even between the dGK and the dCK sequences, 
which is due to the presence of a mitochondrial leader se- 
quence in case of dGK. There are several basic residues in 
this region in dGK, including double arginine residues which 
most likely serve as the site of proteolysis upon entry of the 
protein into the mitochondrial matrix [16,17]. In common 
with most other phosphotransferases mentioned above dGK 
contain a glycine-rich region near the N-terminal, with the 
characteristics of an ATP-binding site [25]. The location of 
the glycine loop in the mammalian proteolysed dGK is almost 
identical to that of the unmodified Lactobacillus enzyme. A 
second region of conserved amino acids is the so-called DRS 
1 2 3 
67 kDa 
45 kDa 
30 kDa 
21 kDa 
Fig. 3. SDS-PAGE of purified recombinant human dGK (lane 1), 
purified bovine dGK (lane 2), and molecular weight standards 
(lane 3). 
* * * *****  
dGKhum MAKSPLEGVSSSRGLHAGRGPRRLSIEGNIAVGKSTFVKL 4~ 
dCKhum MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNI 40 
dGKtac MTV . . . . . . . . . . . . . . . . . . . .  IVLSGPIGAGKSSLTGI 20 
(G1ycine-loop) 
dGKhum LTKTYPEWHVATEPVATWQNIQAAGTQ--- KACTAQS L GN 
dCKhum LKQLCEDWEVVPEPVARWCNVQSTQDEFEELTMSQKNGGN ~ 
dGKtac LSK . . . . .  YLGTNPF . . . . . . . . . . . .  YESV . . . . .  DDNP 38 
dGKhum LLDMMYREPARWSYTFQTFSFLSRLKVQLEPFPEKLLQAR 117 
dCKhum VLQMMYEKPERWSFTF(JTYACLSRIRAQLASLNGKLKDAE 120 
dGKtac VLPLFYENPKKYAFLLQVYFLNTRFR . . . .  SIKSALTDDN 74 
********  
dGKhum KPVQIFERSVYSDRYIFAKNLFENDSLSDIEWHIYQDWHS 157 
dCKhum KPVEFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHD 160 
dGK1ac N---VLDRSIYEDALFFQPANADIGRATPEEVDTYYELLHN 111 
CDRS mot i f )  , , , , , * *  
dGKhum FLLWEFAS--RTTLHGFIYLSASP~VCLKRLY~RAREEEE 195 
dCKhum WMNNQFGO--SLELDGIIYL ATP TCLHRIYERGRNEEQ198 
dGK1ac -MMSELDRMPKKNPDLLVHIOVSYDTMLKRIQKRGRNYE(~ 150 
(A~ginine-rich moti f~ 
dGKhum GIELAYLEQLHGQHEAWLIHKTTKLHFEALMNIPVLVLDV 235 
dCKhum GIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDV 238 
dGKtac ---LSYDPTLE-DYYKRLL-RYYKPWYAKYDYSPKMTIDG 185 
dGKhum ND-DFSEEVTKQEDLMREVNTFVKNL. 261 
dCKhum NE-DFKD---KYESLVEKVKEFLSTL E 261 
dGK1ac DKLDFMASEEDRQEVLNQIVAKLKEMGKLEDDWKPNLVKE 225 
Fig. 4. Multiple alignment of human dGK with human dCK [9] 
and L. acidophilus dGK [24]. Sequence comparisons were performed 
with the DNASTAR program. Basic amino acids presumably in- 
volved in mitochondrial localization signal for dGK are underlined. 
Residues marked with * indicates regions of conservation with other 
members of the deoxynucleoside kinases [18-27]. 
motif which is observed in many viral thymidine kinases 
[26,27] and it appears to be an ERS or possibly a DRY motif 
in the dGK and dCK sequences (Fig. 4). 
A third region with a set of conserved arginines located 
towards the C-terminal end of the proteins can also be iden- 
tified in all these sequences and this motif is presumably also 
involved in phosphate donor binding [24]. Herpes simplex 1 
thymidine kinase, which is responsible for the selectivity of the 
successful antiviral treatment with acyclovir, is known to 
show sequence similarities with human dCK [26,27] and con- 
tains these three sequence motifs. The recent determination of
the 3D structure of the Herpes simplex 1 kinase [28,29] may 
enable the clarification of important structure function rela- 
tionships in the deoxynucleoside kinase family. 
The physiological role of mammalian dGK is not known 
but it is likely that the enzyme is responsible for the supply of 
deoxyribonucleotides for mitochondrial DNA synthesis and in 
cells lacking de novo synthesis of deoxyribonucleotides this 
may be the only pathway leading to the production of purine 
deoxynucleotides. The cloning and sequencing of dGK cDNA 
will help to clarify the function of the enzyme in mitochon- 
drial DNA precursor synthesis, in pharmacological treatments 
with purine deoxynucleoside analogs as well as in situations of 
altered purine nucleoside catabolism such as in PNP defi- 
ciency. 
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